Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 239,483 shares, a growth of 1,955.8% from the June 15th total of 11,649 shares. Based on an average trading volume of 7,749,497 shares, the days-to-cover ratio is presently 0.0 days. Currently, 99.8% of the shares of the company are sold short.
Universe Pharmaceuticals Trading Down 1.3%
Shares of UPC stock traded down $0.07 during mid-day trading on Friday, reaching $5.27. The company’s stock had a trading volume of 308,161 shares, compared to its average volume of 4,370,532. Universe Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $17.96. The firm’s 50-day moving average is $3.69 and its two-hundred day moving average is $3.49.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings raised shares of Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Universe Pharmaceuticals currently has a consensus rating of “Sell”.
Universe Pharmaceuticals Company Profile
Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.
The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.
Featured Articles
- Five stocks we like better than Universe Pharmaceuticals
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
